基因型 | 肽编号 | 肽序列 | 表位来源 |
A*01:01 | 307 | KSDICTDEY | Tyrosinase 243-251 (244S) |
A*02:01 | 2291 | AILALLPAL | Prostate Stem Cell Antigen (PSCA) 105-133 |
A*02:01 | 1920 | ALLTSRLRFI | Telomerase Reverse Transcriptase (hTRT) 615-624 |
A*02:01 | 2083 | FLAEDALNTV | Epithelial Discoidin Domain Receptor 1 (EDDR1) 867-876 |
A*02:01 | 2079 | FLYDDNQRV | Topoisomerase II-alpha-b 828-836 |
A*02:01 | 1386 | GLAPPQHLIRV | p53 187-197 |
A*02:01 | 468 | ILSLELMKL | Receptor for hyaluronic acid-mediated motility (RHAMM) 165-173 |
A*02:01 | 1464 | LTLGEFLKL | Survivin-3A 96-104 |
A*02:01 | 2299 | SLPPPGTRV | p53 149-157 |
A*02:01 | 1403 | VIMPCSWWV | Chondromodulin-I 319-327 |
A*02:01 | 1201 | YMCSFLFNL | Ewing Tumor EZH2 666-674 |
A*02:01 | 61 | YMDGTMSQV | Tyrosinase 369-377 (371D) |
A*02:01 | 447 | YLQVNSLQTV | Telomerase Reverse Transcriptase (hTRT) 988-997 |
A*02:01 | 859 | KLQDASAEV | HM1.24-aa 126-134 |
A*02:01 | 329 | ILLWQPIPV | Prostatic Acid Phosphatase-3 (PAP-3) 135-143 |
A*02:01 | 560 | GLMEEMSAL | Human Mena protein (overexpressed in breast cancer) |
A*02:01 | 813 | FVGEFFTDV | GPC3 144-152 (overexpressed in hepatocellular carcinoma) |
A*02:01 | 75 | YLSGANLNL | Carcinogenic Embryonic Antigen (CEA) 571-579 |
A*02:01 | 157 | VLYRYGSFSV | gp100 (pmel17) 476-485 |
A*02:01 | 250 | VLQELNVTV | Leukocyte Proteinase-3 (Wegener's autoantigen) 169-177 |
A*02:01 | 97 | VISNDVCAQV | Prostate Specific Antigen-1 (PSA-1) 154-163 |
A*02:01 | 390 | SLLMWITQV | NY-ESO-1 157-165 |
A*02:01 | 212 | RLLQETELV | HER-2/neu 689-697 |
A*02:01 | 810 | LIAHNQVRQV | HER-2/neu 85-94 |
A*02:01 | 690 | LLHETDSAV | PSMA/PSM-P1 4-12 |
A*02:01 | 599 | ALDVYNGLL | Prostatic acid phosphatase precursor (PAP) 299-307 |
A*02:01 | 645 | YLNTVQPTCV | EGF-R 1138-1147 |
A*02:01 | 781 | VLDGLDVLL | PRAME 100-108 |
A*02:01 | 689 | VLAGGFFLL | PSMA 27-38 |
A*02:01 | 394 | YLFFYRKSV | mTERT 572-580 |
A*02:01 | 34 | FLWGPRALV | MAGEA3 271-279 |
A*02:01 | 646 | KLFGTSGQKT | EGF-R-479 350-359 |
A*02:01 | 915 | TLPGYPPHV | PAX-5 311-319 |
A*02:01 | 1056 | SLFLGILSV | CD20 188-196 (B cell malignancies) |
A*02:01 | 117 | RLVDDFLLV | Telomerase Reverse Transcriptase 865-873 |
A*02:01 | 208 | LLLLTVLTV | MUC-1 12-20 |
A*02:01 | 205 | LLGRNSFEV | p53 264-272 |
A*02:01 | 600 | ALFDIESKV | PSM P2 (prostate) |
A*02:01 | 1013 | FLGYLILGV | Prostatic Acid Phosphatase-3 (PAP-3) |
A*02:01 | 561 | TMNGSKSPV | hMena 502-510 |
A*02:01 | 391 | LMLGEFLKL | Survivin 96-104 |
A*02:01 | 338 | QLCPICRAPV | Livin/ML-IAP280 175-184 |
A*02:01 | 1181 | SLSEKTVLL | CD59 glycoprotein precursor 106-114 |
A*02:01 | 958 | SLVDVMPWL | Cytochrome p450 1B1 239-248 |
A*02:01 | 214 | KIFGSLAFL | HER-2/neu 369-377 |
A*02:01 | 46 | IMDQVPFSV | gp100 (pmel17) 209-217 |
A*02:01 | 210 | ILHNGAYSL | HER-2/neu 435-443 |
A*02:01 | 85 | ILAKFLHWL | Telomerase 540-548 |
A*02:01 | 249 | HLSTAFARV | G250 (renal cell carcinoma) 217-225 |
A*02:01 | 125 | GVLVGVALI | Carcinogenic Embryonic Antigen (CEA) 694-702 |
A*02:01 | 527 | ALYVDSLFFL | PRAME PRA 300-309 |
A*02:01 | 405 | KLQCVDLHV | Prostate Specific Antigen 146-154 |
A*02:01 | 86 | ALQPGTALL | Prostate Stem Cell Antigen (PSCA) 14-22 |
A*02:01 | 302 | KVAELVHFL | MAGEA3 112-120 |
A*02:01 | 57 | KTWGQYWQV | gp100 (pmel17) 154-162 |
A*02:01 | 389 | GLYDGMEHL | MAGEA-10 254-262 |
A*02:01 | 404 | FLTPKKLQCV | Prostate Specific Antigen-1 (PSA-1) 141-150 |
A*02:01 | 82 | ELAGIGILTV | MelanA / MART 26-35 |
A*02:01 | 171 | KVLEYVIKV | MAGEA1 278-286 |
A*02:01 | 2293 | GLQHWVPEL | BA46 (Lactadherin) 97-106 |
A*02:01 | 2294 | GVRGRVEEI | bcr-abl fusion protein |
A*02:01 | 48 | YLSGADLNL | Carcinoembryonic antigen (CEA)-derived peptide CAP1-6D |
A*02:01 | 2296 | ITDQVPFSV | gp100 (pmel) 209-217 |
A*02:01 | 47 | YLEPGPVTV | gp100 (pmel) 280-288 (288V) |
A*02:01 | 2301 | YLQLVFGIEV | MAGEA2 157-166 |
A*02:01 | 2298 | KVAEELVHFL | MAGEA3 112-120 (alternative version) |
A*02:01 | 49 | SLLMWITQC | NY-ESO-1 157-165 (9C) |
A*02:01 | 2300 | YLGSYGFRL | p53 103-111 |
A*02:01 | 2297 | KLCPVQLWV | p53 139-147 |
A*02:01 | 654 | RMPEAAPPV | p53 65-73 |
A*02:01 | 1787 | RLTSRVKAL | Telomerare Reverse Transcriptase (hTRT) 653-661 |
A*02:01 | 1786 | GLLGASVLGL | Telomerase Reverse Transcriptase (hTRT) 674-683 |
A*02:01 | 381 | LLLTVLTVV | Tumor Mucin Antigen 13-21 |
A*03:01 | 118 | ALLAVGATK | gp100 (pmel17) 17-25 |
A*03:01 | 264 | ATGFKQSSK | bcr-abl 210 kD fusion protein 259-269 |
A*03:01 | 87 | KQSSKALQR | bcr-abl 210 kD fusion protein 21-29 |
A*03:01 | 541 | RISTFKNWPK | Survivin-3A 18-27 (27K) |
A*24:02 | 416 | EYLQLVFGI | MAGEA2 156-164 |
A*24:02 | 421 | TFPDLESEF | MAGEA3 97-105 |
A*24:02 | 209 | TYACFVSNL | Carcinogenic Embryonic Antigen (CEA) 652-660 |
A*24:02 | 417 | TYLPTNASL | HER-2/neu 63-71 |
A*24:02 | 418 | VYGFVRACL | Telomerase reverse transcriptase (hTRT) 461-469 |
A*24:02 | 230 | AFLPWHRLF | Tyrosinase 188-196 |
A*24:02 | 2303 | CYASGWGSI | Prostate Specific Antigen-1 153-161 |
A*24:02 | 238 | VYFFLPDHL | gp100-intron 4 170-178 |
A*24:02 | 1806 | RYCNLEGPPI | Lymphocyte antigen 6 complex locus K (LY6K) 177-186 |
A*24:02 | 2302 | AYACNTSTL | Survivin 80-88 |
B*07:02 | 2304 | LPWHRLFLL | Tyrosinase 208-216 |
B*08:01 | 94 | GFKQSSKAL | bcr-abl 210 kD fusion protein 19-27 |
B*35:01 | 2307 | MPFATPMEA | NY-ESO-1 94-102 |
H-2Db | 1731 | ATFKNWPFL | Murine Survivin 20-28 |
H-2Db | 695 | Abu-Abu-L-Abu-LTVFL | Moloney murine sarcoma virus (MoMSV) GagL 85-93 |
H-2Db | 2199 | FSNSTNDILI | VEGFR2/KDR fragment 1 614-624 |
H-2Db | 1333 | KVPRNQDWL | gp100 (pmel17) 25-33 |
H-2Kb | 185 | SVYDFFVWL | Tyrosinase related protein-2 180-188 |
H-2Kb | 351 | HNTQYCNL | MAGEA5 5-12 |
H-2Kb | 2311 | TVSEFLKL | Murine Survivin 97-104 |
H-2Kd | 275 | DYWGQGTEL | Surface IgG (sA20-Ig) of A20 106-114 |
H-2Kd | 814 | EYILSLEEL | GPC3 298-306 |
H-2Kd | 343 | TYVPANASL | neu/HER-2/Erbb2 proto-oncoprotein 66-74 |
H-2Ld | 150 | LPYLGWLVF | Tumour Antigen P815 35-43 |
